Physiological sexual dysfunction
Drug research and approvals for physiological sexual dysfunction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 107 studies of physiological sexual dysfunction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 107
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 107 recruiting on ClinicalTrials.gov ↗- Platelet-Rich Plasma for Erectile Dysfunction After Radical ProstatectomyNCT07863388 · Not applicable · Herlev and Gentofte Hospital · starts Nov 10, 2026
- Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer TreatmentNCT07685249 · Not applicable · Duke University · starts Nov 1, 2026
- A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction PatientsNCT07899073 · Phase 3 · Hanmi Pharmaceutical Company Limited · starts Oct 1, 2026
- Pudendal Atherosclerosis by IVUS-NIRS in Men With Coronary Artery DiseaseNCT07856199 · Not applicable · Hospital Central Militar · starts Sep 24, 2026
- Tractography-Guided Nerve-Sparing in Prostate CancerNCT07847385 · Not applicable · Massimo Valerio · starts Sep 1, 2026
- Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical ProstatectomyNCT07576335 · Phase 2 · Surgical Outcomes Research Centre (SOuRCe) · starts Aug 31, 2026
- The PANHIS Study: Sexual Health in Spanish-Speaking Adults - A Cross-Sectional Online SurveyNCT07746297 · Not reported · Menoclinica by Palacios · starts Aug 30, 2026
- PRP for Sexual FunctionNCT07920900 · Not applicable · Icahn School of Medicine at Mount Sinai · starts Aug 27, 2026
- Predictors of Religious Orientation Attitudes in Menopausal WomenNCT07797296 · Not reported · KTO Karatay University · starts Aug 26, 2026
- Male Sexual Function and Sexual Quality of Life in Polygamous Versus Monogamous MarriagesNCT07783958 · Not reported · Al-Azhar University · starts Aug 20, 2026
Drug Pipeline
4 in phase 3, 10 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Bremelanotide
- Phase 3 Melanocortin receptor 4 agonist
- Prasterone
- Phase 3 Unknown
- Dapoxetine
- Phase 3 Serotonin transporter inhibitor
- Tibolone
- Phase 3
- Sildenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Testosterone undecanoate
- Phase 2 Androgen Receptor agonist
- Alprostadil
- Phase 2 Prostanoid EP1 receptor agonist
- Oxytocin
- Phase 2 Oxytocin receptor agonist
- Ginkgo
- Phase 2
- Tadalafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Buspirone
- Phase 2 Serotonin 1a (5-HT1a) receptor partial agonist
- Fispemifene
- Phase 2 Estrogen receptor modulator
- PF-00446687
- Phase 2 Melanocortin receptor 4 agonist
- CP-866087
- Phase 2 Mu opioid receptor antagonist
- Bupropion
- Phase 1 Dopamine transporter inhibitor
- Caffeine
- Phase 1 Adenosine receptor antagonist
- Testosterone cypionate
- Phase 1 Androgen Receptor agonist
- Kaempferol
- Phase 1
How Its Trials Ended
44 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 5 whose ending is known, 40% met their primary endpoint, 0% missed it and 60% stopped early.
- Completed, result not reported2557%
- Ongoing920%
- Status unknown511%
- Met its primary endpoint25%
- Stopped: enrollment or feasibility25%
- Stopped: sponsor or business decision12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA